![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="250" height="148"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
Explore News By Topic
01/28/2021
Fifth Anniversary Blue Jacket Fashion Show Featuring Billy Porter, André Leon Talley, Mario Cantone, Mike Woods, Dominic Fumusa and More Goes Virtual to Raise Awareness and Funds for Prostate Cancer Research
NEW YORK, Jan. 28, 2021 -- The fifth annual Blue Jacket Fashion Show in support of the Prostate Cancer Foundation will be held virtually—and with a newly personal approach—at 7:00 p.m. EST on Thursday, February 4, 2021, which is also World Cancer Day. Janssen Oncology, part of the Janssen Pharmaceutical Companies of... Read More
01/11/2021
Promising new treatment strategy for men with drug-resistant prostate cancer
A new experimental drug could offer a promising approach to treating men with advanced prostate cancer which does not respond to existing treatments, or develops resistance to them, researchers report. Their study reveals the chemical structure of a new targeted drug known as CCS1477 and its method of action –... Read More
01/04/2021
Largest, most diverse ever study of prostate cancer genetics brings disparities into focus
"PCF has been funding research to understand and improve African American disparities in prostate cancer for more than 25 years. We believe that Dr. Chris Haiman’s research findings will lead to more effective prostate cancer precision screening strategies for men of West African ancestry. This is why PCF is partnering... Read More
12/01/2020
UCLA, UCSF gain FDA approval for prostate cancer imaging technique
The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new imaging technique for prostate cancer that locates cancer lesions in the pelvic area and other parts of the body... Read More
11/09/2020
VA, Prostate Cancer Foundation to expand genetic services to Veterans through nursing research pilot initiative
WASHINGTON — The U.S. Department of Veterans Affairs (VA) announced today a new nursing research and training collaboration with the Prostate Cancer Foundation (PCF) focused on expanding the role of advanced practice registered (APRN) nurses in the genetic services workforce and the delivery of precision oncology patient care. The expansion includes the creation of... Read More
07/20/2020
Prostate Cancer Metastasis Linked to Revival of Dormant Molecular Program
When prostate cancer progresses to a more-dangerous metastatic state, it does so by resurrecting dormant molecular mechanisms that had guided the fetal development of the prostate gland but had been subsequently switched off, say scientists from Dana-Farber Cancer Institute. The study, an international collaboration with The Netherlands Cancer Institute, was published in Nature... Read More
05/30/2020
ASCO 2020: Blood Test Predicts Response to Prostate Cancer Treatment
A new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track the disease. The non-invasive test is less painful and cheaper than tissue biopsies and can help pick out men who... Read More
05/20/2020
Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The approval by the US Food and Drug Administration... Read More
05/15/2020
Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy
Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical trial i 44% ORR (95% CI 31, 57) and median DOR not evaluable (95% CI 6.4, NE, range in... Read More
05/15/2020
VA Launches Clinical Trial for Veterans with COVID-19 Based on Prostate Cancer Drug
WASHINGTON — Today, the U.S. Department of Veterans Affairs (VA) began a new clinical trial to test a Food and Drug Administration-approved prostate cancer drug as a potential treatment for male Veterans with COVID-19. In a double-blind randomized controlled trial, VA scientists will compare the drug degarelix (trade name Firmagon) to a placebo... Read More